Trial Profile
POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Tamoxifen
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms POLARIS
- Sponsors Pfizer
- 24 Oct 2023 Results assessing real-world impact on outcomes in patients advanced breast cancer, presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results assessing impact of comorbidities on pt quality of life (QoL) using the EORTC-QLQ-C30 questionnaire. presented at the 48th European Society for Medical Oncology Congress
- 23 Feb 2023 Status changed from recruiting to completed.